Financials data is unavailable for this security.
View more
Year on year Pfizer Inc 's revenues fell -41.70% from 100.33bn to 58.50bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from 31.37bn to 2.12bn, a -93.25% decrease.
Gross margin | 70.82% |
---|---|
Net profit margin | 7.16% |
Operating margin | 5.07% |
Return on assets | 1.98% |
---|---|
Return on equity | 4.52% |
Return on investment | 2.39% |
More ▼
Cash flow in USDView more
In 2023, Pfizer Inc increased its cash reserves by 523.29%, or 2.45bn. Cash Flow from Financing totalled 26.07bn or 44.56% of revenues. In addition the company generated 8.70bn in cash from operations while cash used for investing totalled 32.28bn.
Cash flow per share | 1.97 |
---|---|
Price/Cash flow per share | 13.52 |
Book value per share | 16.29 |
---|---|
Tangible book value per share | -6.40 |
More ▼
Balance sheet in USDView more
Current ratio | 1.00 |
---|---|
Quick ratio | 0.729 |
Total debt/total equity | 0.7336 |
---|---|
Total debt/total capital | 0.4225 |
More ▼
Growth rates in USD
SmartText is unavailable
Div yield(5 year avg) | 3.64% |
---|---|
Div growth rate (5 year) | 3.82% |
Payout ratio (TTM) | 221.03% |
EPS growth(5 years) | -7.10 |
---|---|
EPS (TTM) vs TTM 1 year ago | -59.14 |
More ▼